{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:33:44Z","timestamp":1789252424734,"version":"build-2803163510"},"reference-count":179,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research council of the University of Patras","award":["32809"],"award-info":[{"award-number":["32809"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The emergence of high-throughput approaches has had a profound impact on personalized medicine, evolving the identification of inheritable variation to trajectory analyses of transient states and paving the way for the unveiling of response biomarkers. The utilization of the multi-layered pharmaco-omics data, including genomics, transcriptomics, proteomics, and relevant biological information, has facilitated the identification of key molecular biomarkers that can predict the response to therapy, thereby optimizing treatment regiments and providing the framework for a tailored treatment plan. Despite the availability of multiple therapeutic options for chronic diseases, the highly heterogeneous clinical response hinders the alleviation of disease signals and exacerbates the annual burden and cost of hospitalization and drug regimens. This review aimed to examine the current state of the pharmaco-omic approaches performed in psoriasis, a common inflammatory disease of the skin. We sought to identify central studies that investigate the inter-individual variability and explore the underlying molecular mechanisms of drug response progression via biological profiling in psoriatic patients administered with the extended therapeutic armamentarium of psoriasis, incorporating conventional therapies, small molecules, as well as biological drugs that inhibit central pathogenic cytokines involved in the disease pathogenesis.<\/jats:p>","DOI":"10.3390\/ijms24087090","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T02:57:08Z","timestamp":1681268228000},"page":"7090","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5967-9367","authenticated-orcid":false,"given":"Charalabos","family":"Antonatos","sequence":"first","affiliation":[{"name":"Laboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalia","family":"Asmenoudi","sequence":"additional","affiliation":[{"name":"Laboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7202-981X","authenticated-orcid":false,"given":"Mariza","family":"Panoutsopoulou","sequence":"additional","affiliation":[{"name":"Laboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis","family":"Vasilopoulos","sequence":"additional","affiliation":[{"name":"Laboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.1957.72980250010016","article-title":"Drug Reactions, Enzymes, and Biochemical Genetics","volume":"165","author":"Motulsky","year":"1957","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/1479-7364-1-5-375","article-title":"Human Pharmacogenomics: The Development of a Science","volume":"1","author":"Kalow","year":"2004","journal-title":"Hum. Genom."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40364-020-00213-4","article-title":"Application of Pharmacogenetics in Oncology","volume":"8","author":"Ivanov","year":"2020","journal-title":"Biomark. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"DISCO (Deciphering disorders Involving Scoliosis and COmorbidities) Study, Liu, J., Zhou, Y., Liu, S., Song, X., Yang, X.-Z., Fan, Y., Chen, W., Akdemir, Z.C., and Yan, Z. (2018). The Coexistence of Copy Number Variations (CNVs) and Single Nucleotide Polymorphisms (SNPs) at a Locus Can Result in Distorted Calculations of the Significance in Associating SNPs to Disease. Hum. Genet., 137, 553\u2013567.","DOI":"10.1007\/s00439-018-1910-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","article-title":"Pharmacogenomics and Individualized Drug Therapy","volume":"57","author":"Eichelbaum","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving towards Individualized Medicine with Pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"},{"key":"ref_8","first-page":"167","article-title":"Integrating Genotype and Phenotype Information: An Overview of the PharmGKB Project","volume":"1","author":"Klein","year":"2001","journal-title":"Pharm. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1177\/0004867413520050","article-title":"The Role of Pharmacogenomic Testing in Psychiatry: Real World Examples","volume":"48","author":"Dinama","year":"2014","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/03602530903118729","article-title":"New Insights into the Structural Characteristics and Functional Relevance of the Human Cytochrome P450 2D6 Enzyme","volume":"41","author":"Wang","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"ref_11","first-page":"3","article-title":"\u201cOmics\u201d in Pharmaceutical Research: Overview, Applications, Challenges, and Future Perspectives","volume":"13","author":"Yan","year":"2015","journal-title":"Chin. J. Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/bjd.12381","article-title":"Changes in the Level of Serum MicroRNAs in Patients with Psoriasis after Antitumour Necrosis Factor-\u03b1 Therapy","volume":"169","author":"Pivarcsi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.7150\/thno.31144","article-title":"In-Depth Serum Proteomics Reveals Biomarkers of Psoriasis Severity and Response to Traditional Chinese Medicine","volume":"9","author":"Xu","year":"2019","journal-title":"Theranostics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1021\/pr500782g","article-title":"LC\u2013MS Metabolomics of Psoriasis Patients Reveals Disease Severity-Dependent Increases in Circulating Amino Acids That Are Ameliorated by Anti-TNF\u03b1 Treatment","volume":"14","author":"Kamleh","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"125sr1","DOI":"10.1126\/scitranslmed.3003504","article-title":"Treating Human Autoimmunity: Current Practice and Future Prospects","volume":"4","author":"Rosenblum","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_16","first-page":"385","article-title":"High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?","volume":"5","author":"Greiner","year":"2021","journal-title":"Pharm. Econ. Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12375","article-title":"Heritability of Psoriasis in a Large Twin Sample","volume":"169","author":"Skov","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15382","DOI":"10.1038\/ncomms15382","article-title":"Large Scale Meta-Analysis Characterizes Genetic Architecture for Common Psoriasis Associated Variants","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e20202345","DOI":"10.1084\/jem.20202345","article-title":"Single-Cell Analysis of Human Skin Identifies CD14+ Type 3 Dendritic Cells Co-Producing IL1B and IL23A in Psoriasis","volume":"218","author":"Nakamizo","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"BSR20193266","DOI":"10.1042\/BSR20193266","article-title":"Koebner Phenomenon Leading to the Formation of New Psoriatic Lesions: Evidences and Mechanisms","volume":"39","author":"Ji","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/PTT.S126727","article-title":"Drug-Induced Psoriasis: Clinical Perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"PTT"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/etm.2021.9999","article-title":"Infection-provoked Psoriasis: Induced or Aggravated (Review)","volume":"21","author":"Teng","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid Predendritic Cells Initiate Psoriasis through Interferon-\u03b1 Production","volume":"202","author":"Nestle","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The Antimicrobial Peptide LL37 Is a T-Cell Autoantigen in Psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gisondi, P., Del Giglio, M., and Girolomoni, G. (2017). Treatment Approaches to Moderate to Severe Psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112427"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bjd.14219","article-title":"Abnormal Regulation of Fibronectin Production by Fibroblasts in Psoriasis","volume":"174","author":"Vas","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molimm.2020.04.002","article-title":"MiR124-3p\/FGFR2 Axis Inhibits Human Keratinocyte Proliferation and Migration and Improve the Inflammatory Microenvironment in Psoriasis","volume":"122","author":"Xiao","year":"2020","journal-title":"Mol. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kanda, N., Hoashi, T., and Saeki, H. (2021). The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173880"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1523-1747.1998.00446.x","article-title":"Expression of Interleukin-12 Is Increased in Psoriatic Skin","volume":"111","author":"Yawalkar","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 Axis in the Immunopathogenesis of Psoriasis","volume":"129","author":"Nestle","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, Cytokine Profile and Function of Human Interleukin 17\u2013Producing Helper T Cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of Psoriasis and Development of Treatment","volume":"45","author":"Ogawa","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archderm.138.5.591","article-title":"Psoriasis as a Model for T-Cell\u2013Mediated Disease: Immunobiologic and Clinical Effects of Treatment With Multiple Doses of Efalizumab, an Anti\u2013CD11a Antibody","volume":"138","author":"Gottlieb","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"269rv1","DOI":"10.1126\/scitranslmed.3010641","article-title":"Resident Memory T Cells in Human Health and Disease","volume":"7","author":"Clark","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.jaci.2020.11.028","article-title":"Single-Cell RNA Sequencing of Psoriatic Skin Identifies Pathogenic Tc17 Cell Subsets and Reveals Distinctions between CD8+ T Cells in Autoimmunity and Cancer","volume":"147","author":"Liu","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaci.2015.10.046","article-title":"Targeting CD8+ T Cells Prevents Psoriasis Development","volume":"138","author":"Villanova","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2020.10.094","article-title":"CCL20 in Psoriasis: A Potential Biomarker of Disease Severity, Inflammation, and Impaired Vascular Health","volume":"84","author":"Elnabawi","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 Is Expressed in High Levels in Psoriatic Skin and Stimulates Proliferation of Cultured Human Keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2249.1995.tb05525.x","article-title":"IL-8\/IL-8 Receptor Expression in Psoriasis and the Response to Systemic Tacrolimus (FK506) Therapy","volume":"99","author":"Lemster","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/jid.2013.326","article-title":"Heterogeneity of Response to Biologic Treatment: Perspective for Psoriasis","volume":"134","author":"Sterling","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy: Patients Ineligible vs Eligible for Randomized Controlled Trials","volume":"148","author":"Carretero","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/jid.2009.391","article-title":"How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review","volume":"130","author":"Spuls","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1517\/14740330903393732","article-title":"A Review of Acitretin for the Treatment of Psoriasis","volume":"8","author":"Lee","year":"2009","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the Systemic Treatment of Psoriasis Vulgaris\u2014Part 2: Specific Clinical and Comorbid Situations","volume":"35","author":"Nast","year":"2021","journal-title":"Acad. Dermatol. Venereol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.jid.5700096","article-title":"Interaction between Genetic Control of Vascular Endothelial Growth Factor Production and Retinoid Responsiveness in Psoriasis","volume":"126","author":"Young","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/pme-2017-0085","article-title":"The Polymorphisms of Growth Factor Genes (VEGFA & EGF) Were Associated with Response to Acitretin in Psoriasis","volume":"15","author":"Chen","year":"2018","journal-title":"Pers. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.2005.06950.x","article-title":"Apolipoprotein E Gene Polymorphisms Are Associated with Psoriasis but Do Not Determine Disease Response to Acitretin","volume":"154","author":"Campalani","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1684\/ejd.2018.3245","article-title":"Association of IL36RN Mutations with Clinical Features, Therapeutic Response to Acitretin, and Frequency of Recurrence in Patients with Generalized Pustular Psoriasis","volume":"28","author":"Zhu","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.31083\/j.fbl2709266","article-title":"HLA-DQA1 and DQB1 Alleles Are Associated with Acitretin Response in Patients with Psoriasis","volume":"27","author":"Zhou","year":"2022","journal-title":"Front. Biosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13182","DOI":"10.1038\/s41598-018-31352-2","article-title":"Polymorphisms of SLCO1B1 Rs4149056 and SLC22A1 Rs2282143 Are Associated with Responsiveness to Acitretin in Psoriasis Patients","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e4637","DOI":"10.7717\/peerj.4637","article-title":"Frizzled-Related Proteins 4 (SFRP4) Rs1802073G Allele Predicts the Elevated Serum Lipid Levels during Acitretin Treatment in Psoriatic Patients from Hunan, China","volume":"6","author":"Zhou","year":"2018","journal-title":"PeerJ"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/lipd.12173","article-title":"Adipocyte Fatty Acid-Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin","volume":"54","author":"Baran","year":"2019","journal-title":"Lipids"},{"key":"ref_54","first-page":"8","article-title":"Protein Network and Pathway Analysis in a Pharmacogenetic Study of Cyclosporine Treatment Response in Greek Patients with Psoriasis","volume":"23","author":"Antonatos","year":"2023","journal-title":"Pharm. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2217\/pgs.10.166","article-title":"Pharmacogenetics of Psoriasis","volume":"12","author":"Rahman","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_56","first-page":"523","article-title":"A Pharmacogenetic Study of ABCB1 Polymorphisms and Cyclosporine Treatment Response in Patients with Psoriasis in the Greek Population","volume":"14","author":"Vasilopoulos","year":"2014","journal-title":"Pharm. J."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chernov, A., Kilina, D., Smirnova, T., and Galimova, E. (2022). Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112441"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.180.3.1913","article-title":"Identification of Cellular Pathways of \u201cType 1,\u201d Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis","volume":"180","author":"Haider","year":"2008","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e13129","DOI":"10.1111\/dth.13129","article-title":"Evaluation of Expression Pattern of Selected Genes Associated with IL12\/23 Signaling Paths in Psoriatic Patients during Cyclosporine A Therapy","volume":"32","author":"Grabarek","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5114\/ada.2018.77242","article-title":"Variances in the MRNA Expression Profile of TGF-\u03921\u20133 Isoforms and Its TGF-\u0392RI\u2013III Receptors during Cyclosporin a Treatment of Psoriatic Patients","volume":"35","author":"Grabarek","year":"2018","journal-title":"Pdia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/01913120500406616","article-title":"Ultrastructural Findings and Tumor Necrosis Factor-Alpha and Intercellular Adhesion Molecule-1 Expression in Psoriasis Patients Before and After Oral Cyclosporin A Therapy","volume":"30","author":"Seyhan","year":"2006","journal-title":"Ultrastruct. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jamadermatol.2018.5194","article-title":"Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis","volume":"155","author":"Yan","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1159\/000514072","article-title":"The Impact of ANxA6 Gene Polymorphism on the Efficacy of Methotrexate Treatment in Psoriasis Patients","volume":"237","author":"Fan","year":"2021","journal-title":"Dermatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/ced.13100","article-title":"HLA-Cw6-Positive Patients with Psoriasis Show Improved Response to Methotrexate Treatment","volume":"42","author":"West","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_65","first-page":"1","article-title":"The HLA-Cw*06 Allele May Predict the Response to Methotrexate (MTX) Treatment in Chinese Arthritis-Free Psoriasis Patients","volume":"2022","author":"Mao","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/bjd.17704","article-title":"TT Genotype of Rs10036748 in TNIP 1 Shows Better Response to Methotrexate in a Chinese Population: A Prospective Cohort Study","volume":"181","author":"Yan","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/jid.2008.16","article-title":"Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis","volume":"128","author":"Warren","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Gr\u017eelj, J., Marovt, M., Marko, P.B., Mlinari\u010d-Ra\u0161\u010dan, I., Gmeiner, T., and \u0160mid, A. (2021). Polymorphism in Gene for ABCC2 Transporter Predicts Methotrexate Drug Survival in Patients with Psoriasis. Medicina, 57.","DOI":"10.3390\/medicina57101050"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s10517-022-05413-6","article-title":"Genetic Markers of Therapeutic Efficacy of Methotrexate in Patients with Psoriasis","volume":"172","author":"Baskaev","year":"2022","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"111456","DOI":"10.1016\/j.biopha.2021.111456","article-title":"Polymorphisms in GNMT and DNMT3b Are Associated with Methotrexate Treatment Outcome in Plaque Psoriasis","volume":"138","author":"Marko","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/sj.jid.5700808","article-title":"Polymorphisms in Folate, Pyrimidine, and Purine Metabolism Are Associated with Efficacy and Toxicity of Methotrexate in Psoriasis","volume":"127","author":"Campalani","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1111\/jdv.17544","article-title":"A Genome-wide Association Study Identified HLA-C Associated with the Effectiveness of Methotrexate for Psoriasis Treatment","volume":"35","author":"Zhang","year":"2021","journal-title":"Acad. Dermatol. Venereol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2015.0452","article-title":"CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial","volume":"151","author":"Goldminz","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_74","first-page":"42","article-title":"Methotrexate Mechanism of Action in Plaque Psoriasis: Something New in the Old View","volume":"15","author":"Esawy","year":"2022","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jid.2016.09.015","article-title":"Shrinking the Psoriasis Assessment Gap: Early Gene-Expression Profiling Accurately Predicts Response to Long-Term Treatment","volume":"137","author":"Kim","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00228-017-2255-x","article-title":"Pharmacogenetic Markers to Predict the Clinical Response to Methotrexate in South Indian Tamil Patients with Psoriasis","volume":"73","author":"Indhumathi","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jocd.12994","article-title":"Evaluation of the Expression of the Stromal Cell-derived Factor-1 Alpha (CXCL 12) in Psoriatic Patients after Treatment with Methotrexate","volume":"19","author":"Abdelaal","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/jdv.18292","article-title":"iTRAQ-based Quantitative Proteomics Reveals Biomarkers\/Pathways in Psoriasis That Can Predict the Efficacy of Methotrexate","volume":"36","author":"Yan","year":"2022","journal-title":"Acad. Dermatol. Venereol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"937539","DOI":"10.3389\/fimmu.2022.937539","article-title":"Association of the Characteristics of the Blood Metabolome and Gut Microbiome with the Outcome of Methotrexate Therapy in Psoriasis","volume":"13","author":"Qiu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2310\/7750.2012.11124","article-title":"Phototherapy in Psoriasis: A Review of Mechanisms of Action","volume":"17","author":"Wong","year":"2013","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jdermsci.2004.12.017","article-title":"Apoptosis-Deficient Pro Allele of Gene Is Associated with the Resistance of Psoriasis to the UV-Based Therapy","volume":"37","author":"Hairutdinov","year":"2005","journal-title":"J. Dermatol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1365-2133.2010.09985.x","article-title":"Clinical and Genetic Predictors of Response to Narrowband Ultraviolet B for the Treatment of Chronic Plaque Psoriasis: Predictors of Response to NB-UVB for Psoriasis","volume":"163","author":"Ryan","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/jid.2011.53","article-title":"Effective Treatment of Psoriasis with Narrow-Band UVB Phototherapy Is Linked to Suppression of the IFN and Th17 Pathways","volume":"131","author":"Prens","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2133.2006.07628.x","article-title":"Genomic-Scale Analysis of Psoriatic Skin Reveals Differentially Expressed Insulin-like Growth Factor-Binding Protein-7 after Phototherapy","volume":"156","author":"Hochberg","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_85","first-page":"145769","article-title":"Effect of Narrow-Band Ultraviolet B Phototherapy and Methotrexate on MicroRNA (146a) Levels in Blood of Psoriatic Patients","volume":"2015","year":"2015","journal-title":"Dermatol. Res. Pract."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jdermsci.2010.03.018","article-title":"Serum IL-22 Correlates with Psoriatic Severity and Serum IL-6 Correlates with Susceptibility to Phototherapy","volume":"58","author":"Lo","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Verbenko, D.A., Karamova, A.E., Artamonova, O.G., Deryabin, D.G., Rakitko, A., Chernitsov, A., Krasnenko, A., Elmuratov, A., Solomka, V.S., and Kubanov, A.A. (2020). Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11010020"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jdermsci.2017.04.005","article-title":"The Phosphodiesterase 4 Inhibitor Apremilast Inhibits Th1 but Promotes Th17 Responses Induced by 6-Sulfo LacNAc (Slan) Dendritic Cells","volume":"87","author":"Oehrl","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","article-title":"Phosphodiesterase 4 in Inflammatory Diseases: Effects of Apremilast in Psoriatic Blood and in Dermal Myofibroblasts through the PDE4\/CD271 Complex","volume":"28","author":"Schafer","year":"2016","journal-title":"Cell. Signal."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2018.05.039","article-title":"Synergistic Cytokine Effects as Apremilast Response Predictors in Patients with Psoriasis","volume":"142","author":"Garcet","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00011-020-01412-3","article-title":"The Efficacy of in Vivo Administration of Apremilast on Mesenchymal Stem Cells Derived from Psoriatic Patients","volume":"70","author":"Campanati","year":"2021","journal-title":"Inflamm. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41598-020-57542-5","article-title":"Large-Scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects","volume":"10","author":"Medvedeva","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real Life Experience of Apremilast in Psoriasis and Arthritis Psoriatic Patients: Preliminary Results on Metabolic Biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/jdv.12137","article-title":"Glutathione-S-Transferase T1 Genotyping and Phenotyping in Psoriasis Patients Receiving Treatment with Oral Fumaric Acid Esters","volume":"28","author":"Gambichler","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bjd.13128","article-title":"Regulated Genes in Psoriatic Skin during Treatment with Fumaric Acid Esters","volume":"171","author":"Onderdijk","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/ijd.12834","article-title":"The Effect of Dimethyl Fumarate on Gene Expression and the Level of Cytokines Related to Different T Helper Cell Subsets in Peripheral Blood Mononuclear Cells of Patients with Psoriasis","volume":"54","author":"Tahvili","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jdv.16635","article-title":"Disparate Effects of Adalimumab and Fumaric Acid Esters on Cardiovascular Risk Factors in Psoriasis Patients: Results from a Prospective, Randomized, Observer-blinded Head-to-head Trial","volume":"35","author":"Holzer","year":"2021","journal-title":"Acad. Dermatol. Venereol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00403-012-1227-3","article-title":"Serum Levels of Antimicrobial Peptides and Proteins Do Not Correlate with Psoriasis Severity and Are Increased after Treatment with Fumaric Acid Esters","volume":"304","author":"Gambichler","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.2147\/JIR.S380686","article-title":"TYK2 in Immune Responses and Treatment of Psoriasis","volume":"15","author":"Shang","year":"2022","journal-title":"JIR"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and Clinical Effects of Selective Tyrosine Kinase 2 Inhibition with Deucravacitinib in Psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1177\/0300060519847414","article-title":"Efficacy and Safety of Tofacitinib for the Treatment of Chronic Plaque Psoriasis: A Systematic Review and Meta-Analysis","volume":"47","author":"Tian","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/art.41655","article-title":"Contribution of a European-Prevalent Variant near CD83 and an East Asian\u2013Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses","volume":"73","author":"Bing","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib Attenuates Pathologic Immune Pathways in Patients with Psoriasis: A Randomized Phase 2 Study","volume":"137","author":"Krueger","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of Selective JAK1 Inhibitor GSK2586184 for the Treatment of Psoriasis in a Randomized Placebo-Controlled Phase IIa Study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jid.2017.08.040","article-title":"Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment","volume":"138","author":"Kim","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of Tofacitinib on Cardiovascular Risk Factors and Cardiovascular Outcomes Based on Phase III and Long-Term Extension Data in Patients with Plaque Psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/BTT.S252578","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"BTT"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256427","article-title":"Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population","volume":"16","author":"Vasilopoulos","year":"2012","journal-title":"Mol. Diagn. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"811719","DOI":"10.3389\/fphar.2021.811719","article-title":"Tumor Necrosis Factor Alpha -308G\/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-\u03b1 Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1111\/1346-8138.15200","article-title":"Lack of Association of TNFA, TNFRSF1B and TNFAIP3 Gene Polymorphisms with Response to Anti-tumor Necrosis Factor Therapy in Japanese Patients with Psoriasis","volume":"47","author":"Ito","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/pgs-2021-0019","article-title":"Exploring Pharmacogenetic Variants for Predicting Response to Anti-TNF Therapy in Autoimmune Diseases: A Meta-Analysis","volume":"22","author":"Antonatos","year":"2021","journal-title":"Pharmacogenomics"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40291-019-00409-x","article-title":"NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis","volume":"23","author":"Batalla","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/pgs-2017-0143","article-title":"Polymorphisms Associated with Adalimumab and Infliximab Response in Moderate-to-Severe Plaque Psoriasis","volume":"19","author":"Reolid","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40291-017-0261-4","article-title":"HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study","volume":"21","author":"Talamonti","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/14740338.2017.1361404","article-title":"Impact of Pharmacogenomics upon the Therapeutic Response to Etanercept in Psoriasis and Psoriatic Arthritis","volume":"16","author":"Murdaca","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_117","first-page":"70","article-title":"New Polymorphisms Associated with Response to Anti-TNF Drugs in Patients with Moderate-to-Severe Plaque Psoriasis","volume":"18","author":"Cabaleiro","year":"2018","journal-title":"Pharm. J."},{"key":"ref_118","first-page":"e175","article-title":"Polymorphisms Associated with Anti-TNF Drugs Response in Patients with Psoriasis and Psoriatic Arthritis","volume":"33","author":"Reolid","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/jid.2011.376","article-title":"TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis","volume":"132","author":"Tejasvi","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdermsci.2020.05.011","article-title":"Specific Single Nucleotide Polymorphism Genotypes and Association of an IL-12B Polymorphism with Secondary Failure of Infliximab Therapy in Japanese Psoriasis Patients","volume":"99","author":"Torii","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Nani, P., Ladopoulou, M., Papaioannou, E.H., Papagianni, E.D., Antonatos, C., Xiropotamos, P., Kapsoritakis, A., Potamianos, P.S., Karmiris, K., and Tzathas, C. (2023). Pharmacogenetic Analysis of the MIR146A Rs2910164 and MIR155 Rs767649 Polymorphisms and Response to Anti-TNF Treatment in Patients with Crohn\u2019s Disease and Psoriasis. Genes, 14.","DOI":"10.3390\/genes14020445"},{"key":"ref_122","first-page":"494","article-title":"Associations between Functional Polymorphisms and Response to Biological Treatment in Danish Patients with Psoriasis","volume":"18","author":"Loft","year":"2018","journal-title":"Pharm. J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/1346-8138.13412","article-title":"Genetic Prediction of the Effectiveness of Biologics for Psoriasis Treatment","volume":"43","author":"Nishikawa","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/exd.14215","article-title":"Genome-wide Association Analysis of Psoriasis Patients Treated with Anti-TNF Drugs","volume":"29","author":"Sabador","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"968935","DOI":"10.3389\/fphar.2022.968935","article-title":"Genome-Wide Association Analysis of Anti-TNF-\u03b1 Treatment Response in Chinese Patients with Psoriasis","volume":"13","author":"Ren","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Antonatos, C., Panoutsopoulou, M., Georgakilas, G.K., Evangelou, E., and Vasilopoulos, Y. (2022). Gene Expression Meta-Analysis of Potential Shared and Unique Pathways between Autoimmune Diseases under Anti-TNF\u03b1 Therapy. Genes, 13.","DOI":"10.3390\/genes13050776"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e24198","DOI":"10.1002\/jcla.24198","article-title":"MicroRNA-146a and MicroRNA-146b Deficiency Correlates with Exacerbated Disease Activity, and Their Longitude Increment Relates to Etanercept Response in Psoriasis Patients","volume":"36","author":"Shen","year":"2022","journal-title":"Clin. Lab. Anal."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1346-8138.15157","article-title":"Measurement of Circulating MiRNA-125a Exhibits Good Value in the Management of Etanercept-treated Psoriatic Patients","volume":"47","author":"Pei","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00403-015-1594-7","article-title":"Biological Therapy Induces Expression Changes in Notch Pathway in Psoriasis","volume":"307","author":"Skarmoutsou","year":"2015","journal-title":"Arch. Dermatol. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bjd.13721","article-title":"Changes in mRNA Expression Precede Changes in Micro RNA Expression in Lesional Psoriatic Skin during Treatment with Adalimumab","volume":"173","author":"Raaby","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/jdv.12240","article-title":"Effects of Adalimumab Therapy in Adult Subjects with Moderate-to-Severe Psoriasis on Th17 Pathway","volume":"28","author":"Balato","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.intimp.2015.11.005","article-title":"Down-Regulation of the Th1, Th17, and Th22 Pathways Due to Anti-TNF-\u03b1 Treatment in Psoriasis","volume":"29","author":"Luan","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/1346-8138.13631","article-title":"S100A7 Expression Levels in Coordination with Interleukin-8 Indicate the Clinical Response to Infliximab for Psoriasis Patients","volume":"44","author":"Sato","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3892\/etm.2015.2688","article-title":"Effect of TNF-\u03b1 Inhibitors on Transcriptional Levels of pro-Inflammatory Interleukin-33 and Toll-like Receptors-2 and -9 in Psoriatic Plaques","volume":"10","author":"Vageli","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/bjd.13091","article-title":"Increased CCL 22 Expression in Psoriatic Skin Predicts a Good Response to Infliximab Therapy","volume":"171","author":"Kusumoto","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/jid.2010.280","article-title":"Resolved Psoriasis Lesions Retain Expression of a Subset of Disease-Related Genes","volume":"131","author":"Lowes","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Ahn, R., Gupta, R., Lai, K., Chopra, N., Arron, S.T., and Liao, W. (2016). Network Analysis of Psoriasis Reveals Biological Pathways and Roles for Coding and Long Non-Coding RNAs. BMC Genom., 17.","DOI":"10.1186\/s12864-016-3188-y"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jid.2018.04.041","article-title":"A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis","volume":"139","author":"Foulkes","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaci.2021.07.024","article-title":"Cytokine Responses in Nonlesional Psoriatic Skin as Clinical Predictor to Anti-TNF Agents","volume":"149","author":"Tsoi","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jid.2019.09.023","article-title":"Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept","volume":"140","author":"Tomalin","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"105308","DOI":"10.1016\/j.micpath.2021.105308","article-title":"Effectiveness and Safety of Adalimumab in Psoriasis and Its Influence on Gut Microbiome","volume":"162","author":"Zhao","year":"2022","journal-title":"Microb. Pathog."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/exd.14207","article-title":"Anti-tumor Necrosis Factor Drug Responses and Skin-blood DNA Methylation Age: Relationships in Moderate-to-severe Psoriasis","volume":"30","author":"Baccarelli","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjd.15504","article-title":"Epigenetic Biomarkers Associated with Antitumour Necrosis Factor Drug Response in Moderate-to-Severe Psoriasis","volume":"178","author":"Cabaleiro","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/jid.2011.348","article-title":"A Subset of Methylated CpG Sites Differentiate Psoriatic from Normal Skin","volume":"132","author":"Roberson","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.4049\/jimmunol.0900036","article-title":"IL-23 Drives Pathogenic IL-17-Producing CD8+ T Cells","volume":"182","author":"Ciric","year":"2009","journal-title":"J. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2019.0098","article-title":"Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-Analysis","volume":"155","author":"Hannink","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Morelli, M., Galluzzo, M., Scarponi, C., Madonna, S., Scaglione, G.L., Girolomoni, G., Talamonti, M., Bianchi, L., and Albanesi, C. (2022). Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12\/IL-23 Treatment of Patients with Psoriasis. Vaccines, 10.","DOI":"10.3390\/vaccines10111977"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000441719","article-title":"IL12B (P40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis","volume":"232","author":"Galluzzo","year":"2016","journal-title":"Dermatology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.15005","article-title":"Polymorphisms in CD84, IL12B and TNFAIP3 Are Associated with Response to Biologics in Patients with Psoriasis","volume":"176","author":"Coenen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40291-016-0198-z","article-title":"A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-\u03b1 and Anti-IL-12\/23 Agents","volume":"20","author":"Masouri","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"815121","DOI":"10.3389\/fimmu.2021.815121","article-title":"Genome-Wide Association Study of Ustekinumab Response in Psoriasis","volume":"12","author":"Connell","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2340\/00015555-1440","article-title":"IL-20, IL-21 and P40: Potential Biomarkers of Treatment Response for Ustekinumab","volume":"93","author":"Gedebjerg","year":"2013","journal-title":"Acta Derm. Venerol."},{"key":"ref_153","first-page":"e920371-1","article-title":"Indirect Regulation and Equilibrium of P35 and P40 Subunits of Interleukin (IL)-12\/23 by Ustekinumab in Psoriasis Treatment","volume":"26","author":"Zhou","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjd.12175","article-title":"Ustekinumab Improves Psoriasis-Related Gene Expression in Noninvolved Psoriatic Skin without Inhibition of the Antimicrobial Response: Ustekinumab Improves Noninvolved Psoriatic Skin with Normal Antimicrobial Response","volume":"168","author":"Baerveldt","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.jaci.2019.01.017","article-title":"Modulation of Inflammatory Gene Transcripts in Psoriasis Vulgaris: Differences between Ustekinumab and Etanercept","volume":"143","author":"Brodmerkel","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.jaci.2018.11.042","article-title":"Psoriatic Skin Molecular and Histopathologic Profiles after Treatment with Risankizumab versus Ustekinumab","volume":"143","author":"Visvanathan","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23\u2013Specific MAb) Demonstrates Clinical and Molecular Response in Patients with Moderate-to-Severe Psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"865875","DOI":"10.3389\/fimmu.2022.865875","article-title":"Based on Gene Expression Analysis: Low-Density Neutrophil Expression Is a Characteristic of the Fast Responders Treated With Guselkumab for Psoriasis","volume":"13","author":"Lu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/cts.12807","article-title":"Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab","volume":"13","author":"Zhu","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.jid.2018.03.1501","article-title":"Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial","volume":"138","author":"Loesche","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"923769","DOI":"10.3389\/fcell.2022.923769","article-title":"Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients","volume":"10","author":"Paolino","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1111\/jdv.14808","article-title":"Therapy Response Was Not Altered by HLA-Cw6 Status in Psoriasis Patients Treated with Secukinumab: A Retrospective Case Series","volume":"32","author":"Anzengruber","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.16705","article-title":"Secukinumab Shows High Efficacy Irrespective of HLA-Cw6 Status in Patients with Moderate-to-Severe Plaque-Type Psoriasis: SUPREME Study","volume":"179","author":"Costanzo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjd.18013","article-title":"Secukinumab Shows High Efficacy Irrespective of HLA-Cw6 Status in Patients with Moderate-to-severe Plaque-type Psoriasis: Results from Extension Phase of the SUPREME Study","volume":"181","author":"Papini","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jdv.15787","article-title":"Response to IL-17A Inhibitors Secukinumab and Ixekizumab Cannot Be Explained by Genetic Variation in the Protein-coding and Untranslated Regions of the IL-17A Gene: Results from a Multicentre Study of Four European Psoriasis Cohorts","volume":"34","author":"Vugt","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14712598.2021.1862082","article-title":"HLA-Cw6 and Other HLA-C Alleles, as Well as MICB-DT, DDX58, and TYK2 Genetic Variants Associate with Optimal Response to Anti-IL-17A Treatment in Patients with Psoriasis","volume":"21","author":"Morelli","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A Is Essential for Cell Activation and Inflammatory Gene Circuits in Subjects with Psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1038\/jid.2014.268","article-title":"IL-17 Induces Inflammation-Associated Gene Products in Blood Monocytes, and Treatment with Ixekizumab Reduces Their Expression in Psoriasis Patient Blood","volume":"134","author":"Wang","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaci.2019.09.029","article-title":"I\u03baB\u03b6 Is a Key Player in the Antipsoriatic Effects of Secukinumab","volume":"145","author":"Bertelsen","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"100094","DOI":"10.1016\/j.xjidi.2021.100094","article-title":"Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab","volume":"2","author":"Liu","year":"2022","journal-title":"JID Innov."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Seeler, S., Moldovan, L.-I., Bertelsen, T., Hager, H., Iversen, L., Johansen, C., Kjems, J., and Sommer Kristensen, L. (2022). Global CircRNA Expression Changes Predate Clinical and Histological Improvements of Psoriasis Patients upon Secukinumab Treatment. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0275219"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti\u2013IL-17 Receptor Monoclonal Antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short-Term Transcriptional Response to IL-17 Receptor-A Antagonism in the Treatment of Psoriasis","volume":"145","author":"Tomalin","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Piros, \u00c9.A., Szab\u00f3, \u00c1., Rencz, F., Brodszky, V., Wikonk\u00e1l, N., Miheller, P., Horv\u00e1th, M., and Holl\u00f3, P. (2021). Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters\u2019 Levels, but Has No Effect on Body Composition Parameters. Life, 11.","DOI":"10.3390\/life11060535"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12944-021-01441-9","article-title":"Metabolic Profiling Reveals Interleukin-17A Monoclonal Antibody Treatment Ameliorate Lipids Metabolism with the Potentiality to Reduce Cardiovascular Risk in Psoriasis Patients","volume":"20","author":"Cao","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/CM9.0000000000002130","article-title":"Effects of Secukinumab and Adalimumab on Serum Uric Acid Level in Patients with Plaque Psoriasis","volume":"135","author":"Zhao","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s40261-019-00849-7","article-title":"Gut Microbiome in Psoriasis Is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment","volume":"39","author":"Yeh","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"111065","DOI":"10.1016\/j.biopha.2020.111065","article-title":"Dysregulation of the Gut-Brain-Skin Axis and Key Overlapping Inflammatory and Immune Mechanisms of Psoriasis and Depression","volume":"137","author":"Wang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Marek-Jozefowicz, L., Czajkowski, R., Borkowska, A., Nedoszytko, B., \u017bmijewski, M.A., Cuba\u0142a, W.J., and Slominski, A.T. (2022). The Brain\u2013Skin Axis in Psoriasis\u2014Psychological, Psychiatric, Hormonal, and Dermatological Aspects. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020669"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7090\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:14:13Z","timestamp":1760123653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":179,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24087090"],"URL":"https:\/\/doi.org\/10.3390\/ijms24087090","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}